NextPlat Corp — Third Quarter 2026 Earnings Summary

NextPlat Corp reported third-quarter 2026 consolidated revenue of approximately $10.5 million, a decrease from $13.8 million in the prior year period, driven by lower reimbursement rates and reduced retail prescription volumes. Despite the revenue decline, the company achieved a consolidated gross margin of 35.0%, a significant improvement from 19.9% in the same period last year, largely due to a 300% increase in pharmacy contract revenue. Net loss attributable to common stockholders narrowed by 66% to approximately $0.7 million, or $0.28 per diluted share, compared to $2.2 million in the prior year. The company ended the quarter with $11.2 million in cash and noted a 72% year-over-year growth in higher-margin 340B prescription volumes.